Incretin Atlas › Trials › Phase 3 weight management (ChiCTR1900023428)
Phase 3 weight management (ChiCTR1900023428)
Beinaglutide · obesity
Design
- Molecule(s)
- Beinaglutide
- Population
- obesity
- Phase
- 3
- Participants
- 282
- Duration
- 16 weeks
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.2 mg TID | obesity china | 16 | 282 | — | —−6.0 % vs −2.4 % estimand not specified | — | 5.9 vs 0.7 | — | 49.3 vs 7.1 | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (3)
- 0.2 mg TID · weight_unsp · publication
Mean body weight change from baseline to week 16 was -6.0% and -2.4% in the beinaglutide (n = 282) and placebo (n = 138) groups
- 0.2 mg TID · nausea · publication
Nausea (transient and mild-to-moderate) was the most common adverse event in the beinaglutide group (49.3% vs. 7.1% [placebo]).
- 0.2 mg TID · ae_dc · publication
More patients receiving beinaglutide discontinued treatment because of adverse events (5.9% vs. 0.7% [placebo]).
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: Phase 3 weight management (ChiCTR1900023428). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/phase-3-weight-management/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.